cerivastatin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors 577 145599-86-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • baycol
  • cerivastatin
  • baychol
  • cerivastatin sodium
  • cerivastatin sodium salt hydrate
Cerivastatin is a competitive inhibitor of HMG-CoA reductase, which is responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of sterols, including cholesterol. The inhibition of cholesterol biosynthesis by cerivastatin reduces the level of cholesterol in hepatic cells, which stimulates the synthesis of LDL receptors, thereby increasing the uptake of cellular LDL particles. The end result of these biochemical processes is a reduction of the plasma cholesterol concentration.
  • Molecular weight: 459.56
  • Formula: C26H34FNO5
  • CLOGP: 3.56
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 99.88
  • ALOGS: -5.04
  • ROTB: 11

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 195 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 24 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.33 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 26, 1997 FDA BAYER PHARMS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AA06 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
HMG CoA reductase inhibitors
MeSH PA D000924 Anticholesteremic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Mixed hyperlipidemia indication 267434003
Kidney disease contraindication 90708001 DOID:557
Hemorrhagic cerebral infarction contraindication 230706003
Disease of liver contraindication 235856003 DOID:409
Rhabdomyolysis contraindication 240131006
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.05 acidic
pKa2 13.1 acidic
pKa3 13.99 acidic
pKa4 5.78 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme INHIBITOR IC50 8 WOMBAT-PK CHEMBL
Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor WOMBAT-PK
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme IC50 8.55 CHEMBL

External reference:

IDSource
4021111 VUID
N0000148566 NUI
D00889 KEGG_DRUG
143201-11-0 SECONDARY_CAS_RN
4021111 VANDF
4024119 VANDF
C0718827 UMLSCUI
CHEBI:3558 CHEBI
116 PDB_CHEM_ID
CHEMBL1477 ChEMBL_ID
CHEMBL1200563 ChEMBL_ID
DB00439 DRUGBANK_ID
C086276 MESH_SUPPLEMENTAL_RECORD_UI
446156 PUBCHEM_CID
2950 IUPHAR_LIGAND_ID
7083 INN_ID
AM91H2KS67 UNII
215567 RXNORM
11450 MMSL
4398 MMSL
d04140 MMSL
006489 NDDF
006490 NDDF
108596008 SNOMEDCT_US
108597004 SNOMEDCT_US
373443008 SNOMEDCT_US

Pharmaceutical products:

None